Antiscleroma effectiveness of certain Bacillus subtilis strains studied in vitro and in vivo.
Antagonistic activity of approximately 200 Bacillus subtilis cultures vs. Klebsiella rhinoscleromatis clinical strains in experiments on solid and liquid nutrient media, and in experiments on laboratory animals has been studied. 16 B. subtilis strains characterized by a vivid antiscleroma activity in vivo have been selected. Maximum preventive and therapeutical influence of the B. subtilis strain 1119 upon the flow of experimental acute septic and lung scleroma infection has been determined. While co-cultivating the test cultures under study (B. subtilis 1119 and K. rhinoscleromatis 230), a significant titer decline and complete klebsiella's growth suppression on the 8th-12th days provided the certain concentrations of the antagonistic microbes have been shown.